Navigation Links
BIDMC investigator James Mier, M.D., awarded prominent grant for kidney cancer research
Date:3/20/2013

BOSTON -- James W. Mier, MD, an investigator in the Division of Hematology/Oncology and Director of Basic Research for the Biologic Therapy Program at Beth Israel Deaconess Medical Center (BIDMC), has been awarded an AACR-Kure It Grant for Kidney Cancer Research from the American Association for Cancer Research (AACR) and the nonprofit organization Kure It. The $250,000 award will be presented to Mier on April 9, during the 2013 AACR Annual Meeting in Washington, DC.

The AACR Kure-It grants provide support for innovative translational kidney cancer research designed to improve the survival and quality of life of patients with kidney cancer. Mier is one of only two recipients of the two-year grants.

Mier's research focuses on tumor angiogenesis in renal cell carcinomas and an understanding of how and why renal cell carcinomas develop resistance to VEGF (vascular endothelial growth factor) inhibitors. "An immediate challenge in kidney cancer concerns determining what drives resistance to VEGF inhibition and how to overcome it," explains Mier, an Associate Professor of Medicine at Harvard Medical School and investigator in the Dana-Farber/Harvard Cancer Center.

Common mutations in kidney cancer turn on genes that signal oxygen deprivation. This promotes the growth of new blood vessels and alters cancer cell metabolism towards pathways that support more rapid growth, proliferation and metastasis. A tumor's dependence on new blood vessel growth, known as angiogenesis, makes it sensitive to anti-angiogenesis drugs, which have been used to treat kidney cancer. However, over time, kidney cancer can become resistant to these agents.

But as Mier explains, unlike in lung cancer and other cancers, kidney cancer's resistance to VEGF inhibitor drugs does not result from the cancer cells acquiring new mutations. "Instead, the kidney tumor makes reversible, metabolic adaptations to survive hypoxia, the depletion of oxygen induced by the loss of vascular supply," he explains. In addition, kidney tumors also adapt to VEGF inhibitor agents by disabling the important tumor suppressor p53.

The new AACR-Kure It grant will support Mier's preclinical work developing a way to foil kidney cancer's dual-survival strategy and prevent or delay resistance to VEGF inhibitor drugs. "We are finding that by inhibiting an enzyme called HDM2which tags p53 for deactivation we can raise p53 activity levels and block the influx of myeloid cells into the tumor," explains Mier. "HDM2 inhibitors thus both promote cell death and suppress a resistance strategy." His laboratory will explore the mechanism by which HDM2 antagonists and VEGF-targeted drugs act together to block tumor angiogenesis and induce disease regression in renal cell carcinomas.

"The Mier Lab has long been a leader in improving our understanding of melanoma and kidney cancer biology," adds David McDermott, MD, Co-director of the Kidney Tumor Program and Clinical Director of the Biologic Therapy Program at BIDMC. "This grant is well deserved recognition of their efforts. With HDM2 antagonists entering the clinic, we hope to bring this novel combination therapy to patients within the next year."

A graduate of the Indiana University School of Medicine, Mier completed his internship and residency at Emory University and received oncology training at the National Cancer Institute in the Laboratory of Tumor Cell Biology.

"I am honored to have been selected for this grant and am grateful to Kure It and the AACR for making the funds available," said Mier. "Everyone in my lab feels encouraged by this award. We are planning to use the funds to carry out preclinical studies of novel agents that may prove useful in patients with renal cell carcinoma."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. BIDMCs Mark Andermann, Ph.D., receives Smith Family Foundation Biomedical Research Award
2. BIDMC and Diagnostics For All create first low-cost, paper-based, point of care liver function test
3. Toddler functionally cured of HIV infection, NIH-supported investigators report
4. ANY LAB TEST NOW®’s Terri McCulloch Details the Misconceptions about Drug and DNA Testing to Legal Investigators
5. UNCs Aravind Asokan to receive ASGCT 2013 Outstanding New Investigator Award
6. IOF Young Investigator Awards in Kuala Lumpur recognize high-quality research abstracts
7. Regenstrief investigator inducted into medical informatics honor society
8. 22 young group leaders recognized as European Molecular Biology Organization Young Investigators
9. Philippe Généreux, MD, presented with 2012 TCT Young Investigator Award
10. LA BioMed investigator, Dr. Rodney White, receives the 2012 Golden Goose Award
11. Hospital for Special Surgery investigators receive National Football League grant for PRP research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... Boston Children’s Hospital ... rehearse tough medical situations or practice tricky or rare procedures in an environment that ... the SIM Center is also available to inventors and “hackers” to develop and test ...
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter ... or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 ... Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the ...
(Date:5/3/2016)... ... 03, 2016 , ... Intrigma, the leading provider of vital ... expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler (a part ... The Portland, Oregon based health system conducted a one-year pilot of the Efficient ...
(Date:5/3/2016)... ... 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in West Hollywood , ... existing patients. Cosmetic dentistry allows patients to improve the aesthetics of their smiles. These ... minor or more serious cosmetic flaws. These specials allow patients to achieve their dream ...
(Date:5/3/2016)... South Miami, FL (PRWEB) , ... May 03, 2016 , ... ... to support both its Grow & Climb children and youth programs in South Miami. ... for several years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
Breaking Medicine Technology: